Flash FinanceUS
After hours S&P 5007,376.86+0.31% Nasdaq24,579.42+1.09% Dow 3051,285.73-0.46% Russell 20002,754.11+0.89% Nasdaq-10026,989.99+1.35% MidCap 4003,602.50+0.56% SmallCap 6001,673.98+0.05% VIX25.64-9.01% 10Y Yield4.86+0.45% Close of Nov 06, 2026
AI brief of an SEC Form 8-K · Allarity Therapeutics, Inc. (ALLR)

Allarity Updates on DRP Technology, Patents and In-House Lab for Stenoparib

Neutral Impact 2 of 5 product/contract Written later

Allarity Therapeutics announced an update on its Drug Response Predictor (DRP) technology, recently awarded patents and CLIA-certified in-house lab, which it says support stenoparib's clinical development and external partnership opportunities. The filing contains no financial results, guidance or financing figures, so the update is a development-stage business announcement rather than a measure of current performance.

Key points

  • Recently awarded patents and CLIA certification of the in-house lab allow Allarity to extend the test as a companion diagnostic and retain sole control of the clinical test
  • The stenoparib-DRP is a 414-gene expression signature; an exploratory analysis presented at AACR 2026 linked higher DRP scores to longer overall survival in a prior Phase 2 ovarian cancer cohort
  • Allarity states stenoparib remains its principal development focus, with external partnerships an additional opportunity

The filing

CompanyAllarity Therapeutics, Inc. (ALLR)
Form8-K, current report
Filed with the SECOct 1, 2026, 8:00 AM ET
Accession number0001213900-26-105457

Items reported: 8.01 Other Events

Read the filing on SEC.gov ↗

Written by AI on Nov 9, 2026, 11:44 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on October 01, 2026.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.